Movement disorders

IntelGenx Announces Research Collaboration with Renowned Neurologist to Evaluate Montelukast VersaFilm® for the Treatment of Parkinson’s Disease

Retrieved on: 
Thursday, February 9, 2023
Disease, Movement disorders, Neurodegeneration, Parkinson, Cysteinyl leukotriene receptor 1, Karolinska Institute, Immunomodulation, Trial of the century, Principal, Clinical neuroscience, Per Svenningsson, TSX, Swedish Research Council, Government budget balance, Parkinson's disease, Intellectual property, Lewy body, Clinical trial, Alzheimer's disease, Leukotriene, SCI, Research, Doctor of Philosophy, Pharmaceutical industry, MD, PD, Study

$2 million USD) awarded by the Swedish Research Council, Sweden’s largest governmental research funding body.

Key Points: 
  • $2 million USD) awarded by the Swedish Research Council, Sweden’s largest governmental research funding body.
  • IntelGenx will supply Dr. Svenningsson with both active and placebo films to be used in the 18-month treatment regimen for study participants.
  • Upon completion of the Study, IntelGenx will retain the intellectual property rights and use the findings to further develop its Montelukast VersaFilm® program for Parkinson's disease treatment.
  • 2 Wallin, J; Svenningsson, P. Potential Effects of Leukotriene Receptor Antagonist Montelukast in Treatment of Neuroinflammation in Parkinson’s Disease.

APRINOIA Therapeutics and ROSS Acquisition Corp II Announce Business Combination Agreement to Create Publicly Listed Company Focused on Neurodegenerative Diseases

Retrieved on: 
Wednesday, January 18, 2023
PET, PSP, ROSS, CNS, Therapy, Frontotemporal dementia, Acquisition, Alzheimer's disease, Neurodegeneration, Business, Pub, Combination, Parkinson's disease, Research, FTD, Physician, Alpha-synuclein, MSA, White & Case, Corticobasal degeneration, Multiple system atrophy, Business architecture, FDA, Cooley LLP, Tauopathy, NYSE, AD, Biogen, LLP, Webcast, Dementia, TDP43, Commerce, RMB, Patient, Central nervous system, Antibody, Movement disorders, Bristol Myers Squibb, Pharmaceutical industry, Security (finance), Medical imaging, Fine chemical, Financial adviser

PALM BEACH, Fla. and CAMBRIDGE, Mass., Jan. 18, 2023 /PRNewswire/ -- APRINOIA Therapeutics Inc. ("APRINOIA"), a clinical-stage biotechnology company focused on neurodegenerative diseases such as Alzheimer's Disease ("AD") and Progressive Supranuclear Palsy ("PSP"), and Ross Acquisition Corp II (NYSE: ROSS, ROSS.U, ROSS WS) ("ROSS"), a special purpose acquisition company founded by former Commerce Secretary Wilbur Ross, today announced that they have entered into a definitive agreement (the "Business Combination Agreement") for a business combination (the "Business Combination"). 

Key Points: 
  • APRINOIA and ROSS Acquisition Corp II: Business Combination Agreement Create Public Co., Neurodegenerative Target
    ROSS and APRINOIA are combining at an implied fully diluted transaction equity value of US$280 million for APRINOIA.
  • ROSS has entered into the Business Combination Agreement with APRINOIA, pursuant to which APRINOIA and ROSS will each become a wholly owned subsidiary of the combined company, APRINOIA Therapeutics Holdings Limited, a newly formed entity ("PubCo").
  • APRINOIA and Ross Acquisition Corp II will be hosting an investor call and slide presentation at 4:30 pm ET on Wednesday, January 18, 2023.
  • White & Case LLP acted as legal advisor to ROSS in connection with the proposed Business Combination.

Children's Hospital of Orange County breaks ground on new tower on Orange campus

Retrieved on: 
Tuesday, January 17, 2023
BrainScope Company, Inc., McCarthy, CannonDesign, Learning, Research institute, Hospital, Health, CHOC, Research, Primary care network, Orange County, Children's Hospital of Orange County, Patient, Radiation, Movement disorders, Main Street, Interior design, Management, FirstBank Southwest Tower

ORANGE, Calif., Jan. 17, 2023  /PRNewswire/ -- Children's Hospital of Orange County (CHOC) has broken ground on a nine-story tower at its main campus in Orange that will house a variety of pediatric outpatient services in a soothing and inviting patient- and family-centered environment.

Key Points: 
  • The 330,000-sq.-ft. Southwest Tower, on Main Street and CHOC Court just north of the 22 Freeway, will open in phases beginning in mid-2025.
  • "I'd like to express my gratitude to the providers, executives, and staff who since 2019 have been working hard to bring to life our vision for this beautiful new tower."
  • "The Southwest Tower will create a one-stop shop, so to speak, for patients and families who currently are seen across numerous specialties.
  • CHOC's construction partners on the Southwest Tower also worked on the Bill Holmes Tower, which opened in 2013.

Emalex Biosciences Publishes Phase 2b Results for Tourette Syndrome Candidate in Pediatrics

Retrieved on: 
Wednesday, January 11, 2023
Paragon, Clinical trial, Injury, Pain, Disease, Cincinnati Children's Hospital Medical Center, Insomnia, MD, Distress, Yale Global Tic Severity Scale, Tourette syndrome, Ecopipam, Tic, Social stigma, Patient, Mortality, Pediatrics, Weight gain, Antipsychotic, Somnolence, Fatigue, Headache, Editor's Note, Hospital, Movement disorders, Pharmaceutical industry, Birth control

CHICAGO, Jan. 11, 2023 /PRNewswire/ -- A Phase 2b clinical trial involving more than 150 children and adolescents with Tourette syndrome found ecopipam significantly reduced the total number of tics compared to placebo, according to a study published today in the journal Pediatrics.

Key Points: 
  • The study, known as the D1AMOND trial, was an international, multicentered randomized, placebo-controlled trial of ecopipam in Tourette syndrome.
  • The primary outcome was the mean change in Yale Global Tourette Severity Total Tic Score.
  • The key secondary outcome of Clinical Global Impression of Tourette Syndrome Severity also showed improvement in the ecopipam group (p= 0.03).
  • Ecopipam is the lead candidate for Emalex Biosciences, a clinical-stage biopharmaceutical company founded by Paragon Biosciences.

Wren Builds Out Scientific Advisory Board for Neurodegenerative Diseases

Retrieved on: 
Wednesday, January 4, 2023
Dementia, Medical laboratory, University of Kansas Medical Center, Essential tremor, Neurodegeneration, MIND, University of Nevada, Reno, MTR, School, Achucarro Basque Center for Neuroscience, Drug discovery, Lewy body, Parkinson's disease, Drug development, Neuroinflammation, Science Publishing Group, University, Perelman School of Medicine at the University of Pennsylvania, Doctor of Science, Pathology, Ikerbasque, Therapy, MSA, ALS, Doctor of Philosophy, SAB, Research, Multiple system atrophy, Coronavirus Scientific Advisory Board (Turkey), Movement disorders, Pharmaceutical industry, Medical device, Alzheimer's disease, Neuroscience, Neurology, Wren, MD

BOSTON, Jan. 4, 2023 /PRNewswire/ -- Wren Therapeutics announced today a number of new members to its Scientific Advisory Board.

Key Points: 
  • BOSTON, Jan. 4, 2023 /PRNewswire/ -- Wren Therapeutics announced today a number of new members to its Scientific Advisory Board.
  • "Each of our SAB members brings unrivaled scientific expertise across key areas of neurodegenerative disease biology, preclinical development, and clinical testing that will be invaluable as we advance our first-in-class small-molecule drugs for Parkinson's disease, Alzheimer's disease, and ALS into clinical trials."
  • He has been recognized for this research and leadership contributions in the field of Alzheimer's disease through numerous awards.
  • Her laboratory specializes in the identification and treatment of disease targets in neurodegenerative conditions through translational modeling.

Alterity Therapeutics to Participate in the Sachs Associates 6th Annual Neuroscience Innovation Forum

Retrieved on: 
Tuesday, January 3, 2023
SAN, Drug discovery, Neuropsychiatry, Parkinson's disease, Disease, Movement disorders, ATH, Conference, Neurodegeneration, Multimedia, CNS, ASX, Therapy, Ophthalmology, Alterity, Pharmaceutical industry, Parkinsonism

MELBOURNE, Australia and SAN FRANCISCO, Jan. 3, 2023 /PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that David Stamler, M.D., Chief Executive Officer will participate in the Sachs Associates 6th Annual Neuroscience Innovation Forum (NIF).

Key Points: 
  • MELBOURNE, Australia and SAN FRANCISCO, Jan. 3, 2023 /PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that David Stamler, M.D., Chief Executive Officer will participate in the Sachs Associates 6th Annual Neuroscience Innovation Forum (NIF).
  • The forum is taking place Sunday, January 8, 2022, as part of the activities surrounding the annual J.P. Morgan Healthcare Conference.
  • At the conference, Dr. Stamler will be featured on a panel entitled, "New Approaches to Parkinson's and Movement Disorders."
  • Alterity Therapeutics is a clinical stage biotechnology company dedicated to creating an alternate future for people living with neurodegenerative diseases.

Clinical ink Selected for Global Late Phase Parkinson’s Disease Programs

Retrieved on: 
Thursday, December 15, 2022
Movement, Diagnosis, Drug discovery, Human, Movement disorders, MDS, Guest appearance, Cros, Moca, Critical path, Clinical, Research, Biomarker, PGI, Patient, CGI, Medical imaging

This late-phase clinical development program follows patients over the course of eighteen months and aims to identify measures that can detect Parkinson’s disease progression before the onset of significant symptoms.

Key Points: 
  • This late-phase clinical development program follows patients over the course of eighteen months and aims to identify measures that can detect Parkinson’s disease progression before the onset of significant symptoms.
  • By adopting Clinical ink’s BrainBaselineä platform, researchers are now able to access essential insights into Parkinson’s disease progression via remotely monitored sensor biometrics and wearable data collected passively and during fit-for-purpose active tasks.
  • Clinical ink is the global life science company that brings data, technology, and patient science together.
  • By harnessing digital data, we power sponsors, CROs, researchers, and patients to recenter decentralized trials and rewrite the clinical development experience.

Clinical ink Selected for Global Late Phase Parkinson’s Disease Programs

Retrieved on: 
Wednesday, December 14, 2022
Movement, Diagnosis, Drug discovery, Human, Movement disorders, MDS, Guest appearance, Cros, Moca, Critical path, Clinical, Research, Biomarker, PGI, Patient, CGI, Medical imaging

This late-phase clinical development program follows patients over the course of eighteen months and aims to identify measures that can detect Parkinson’s disease progression before the onset of significant symptoms.

Key Points: 
  • This late-phase clinical development program follows patients over the course of eighteen months and aims to identify measures that can detect Parkinson’s disease progression before the onset of significant symptoms.
  • By adopting Clinical ink’s BrainBaselineä platform, researchers are now able to access essential insights into Parkinson’s disease progression via remotely monitored sensor biometrics and wearable data collected passively and during fit-for-purpose active tasks.
  • Clinical ink is the global life science company that brings data, technology, and patient science together.
  • By harnessing digital data, we power sponsors, CROs, researchers, and patients to recenter decentralized trials and rewrite the clinical development experience.

Praxis Precision Medicines and UCB Announce Epilepsy Research Collaboration

Retrieved on: 
Tuesday, December 13, 2022
Judgement, CNS, Security (finance), Central nervous system disease, Epilepsy, Movement disorders, Drug development, KCNT1, Disease, UCB, Brain, Therapy, Pharmaceutical industry, Praxis

BOSTON, Dec. 13, 2022 (GLOBE NEWSWIRE) -- Praxis Precision Medicines , Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company, and UCB (EURONEXT BRUSSELS: UCB), a global biopharmaceutical company, today announced a strategic collaboration, based upon Praxis’ PRAX-020 program, for the discovery of small molecule therapeutics as potential treatments of KCNT1 related epilepsies.

Key Points: 
  • BOSTON, Dec. 13, 2022 (GLOBE NEWSWIRE) -- Praxis Precision Medicines , Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company, and UCB (EURONEXT BRUSSELS: UCB), a global biopharmaceutical company, today announced a strategic collaboration, based upon Praxis’ PRAX-020 program, for the discovery of small molecule therapeutics as potential treatments of KCNT1 related epilepsies.
  • “Our internal research efforts give us confidence that small molecules can selectively inhibit the KCNT1 channel, and potentially could be an effective treatment for individuals suffering from KCNT1 related epilepsy.
  • Praxis has established a broad portfolio including multiple programs across movement disorders and epilepsy, with four clinical-stage product candidates.
  • Although Praxis’ forward-looking statements reflect the good faith judgment of its management, these statements are based only on information and factors currently known by Praxis.

uniQure Highlights Therapeutic Potential of AMT-260 in Refractory Temporal Lobe Epilepsy (rTLE) at Virtual Research & Development Event

Retrieved on: 
Tuesday, November 29, 2022
Research, Temporal lobe epilepsy, Patient, Epilepsy, Head, Seizure, Compte rendu, Gene, Harvard Medical School, IND, Temporal lobe, Safety, Knowledge, Fabry disease, Brain, Primate, Learning, Mortality, Neoplasm, Annual report, GRIK2, GLP, Central nervous system, MD, TLE, CNS, Webcast, Disease, Risk, Health, Memory, Birth defect, Huntington's disease, Neurology, Hope, MicroRNA, Haemophilia, AAV, Hippocampus, Neuron, FDA, Movement disorders, Pharmaceutical industry, Vaccine, Medical device, Brigham

LEXINGTON, Mass. and AMSTERDAM, the Netherlands, Nov. 29, 2022 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, hosted a virtual investor event focused on AMT-260, an AAV gene therapy for refractory temporal lobe epilepsy (rTLE) and other focal epilepsies. The event featured a presentation from rTLE clinical expert Ellen Bubrick, MD, associate chair of Neurology at Harvard Medical School and director of the Epilepsy Surgery Program at Brigham and Women’s Hospital in Boston, MA on the unmet medical need of patients with rTLE. The presentation highlighted preclinical data that supports the safety and tolerability of AMT-260 and plans for its clinical development, as well as uniQure’s miQURE™ and linQURE™ technology platforms that allow the Company to use miRNAs to safely reduce the expression of genes in the brain. The Company also highlighted its progress in developing a commercial-scale AAV manufacturing platform. A replay of the investor event is available here.

Key Points: 
  • The full virtual research and development event program was webcast live under the Investors section of uniQures website at www.uniQure.com .
  • Temporal lobe epilepsy (TLE) is epilepsy that starts in the temporal lobe area of the brain.
  • About 80% of all temporal lobe seizures start in the mesial temporal lobe, with seizures often starting in or near the hippocampus which controls memory and learning.
  • Patients with refractory temporal lobe epilepsy (rTLE) experience increased morbidity, excess mortality, and poor quality of life.